… has orphan drug designation (ODD) in the U.S. and Europe. Partnership with Foundation Fighting Blindness (FFB) where … and planned to start in 2018 subject to a potential partnership. Eluforsen has FDA Fast Track designation and ODD …
… in preclinical models, a robust IP estate, a fruitful partnership with Eli Lilly, and cash runway into mid-2026.” … with potential additional milestone income from existing partnership, and potential option to exercise for expansion …
In line with corporate strategy update in April, ProQR to focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas; update on initial pipeline targets expected in late 2022/early 2023
Additi
… In parallel, ProQR will continue to execute on its partnership with Lilly and selectively enter into additional partnerships designed to advance and capture the full …
Divestment of sepofarsen and ultevursen ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued advancement of pipeline
€129 M cash and cash equivalents as of June 30, 2023 providing runway into mid-2026
… our preclinical proof of concept data for the platform, a partnership with Eli Lilly, a leading IP position, and strong … Lilly and Company (Lilly). ProQR may selectively form new partnerships, which could include multi-target discovery …
Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas; initial pipeline targets to be disclosed in early 2023 with Analyst and Investor R&D event to be held in Q1 2023
Management Team appointments and p
… 2A Foundation Fighting Blindness and ProQR enter into a partnership to develop QR-421a for Usher syndrome type 2A, … today announced that they have entered into a partnership to develop QR-421a for Usher syndrome 2A caused …
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1
Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas
Stre